This observation has recently been confirmed in HER2+ EBC: pCR is strongly prognostic for EFS and OS in individual patients [23], but it is not associated with better EFS and OS in neoadjuvant trials of HER2+ operable breast cancer [24]. The gene discussed is ERBB2; the disease is breast cancer.